tiprankstipranks
GSK says MenABCWY combination vaccine candidate met all 11 primary endpoints
The Fly

GSK says MenABCWY combination vaccine candidate met all 11 primary endpoints

GSK plc announced "positive headline results" from the phase III trial evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. "GSK‘s MenABCWY vaccine candidate combines the antigenic components of its licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY). All primary endpoints were met, including the non-inferiority of the vaccine candidate for all five Neisseria meningitides serogroups (A, B, C, W, and Y) compared to licensed meningococcal vaccines Bexsero and Menveo in terms of an immune response. In addition, the vaccine candidate was well tolerated, with a safety profile consistent with Bexsero and Menveo. Invasive meningococcal disease, a major cause of meningitis and septicaemia, is an uncommon but serious illness that can cause life-threatening complications or even death, typically amongst previously healthy children and adolescents. Among those contracting meningococcal diseases, one in ten will die, sometimes in as little as 24 hours, despite treatment. One-in-five survivors suffers long-term consequences, such as brain damage, amputations, hearing loss and nervous system problems. Five Neisseria meningitides serogroups (A, B, C, W, and Y) account for nearly all IMD cases in most of the world. As yet, no licensed combination vaccine offers protection against these serogroups in a single vaccine. Currently, in the US, two separate vaccines needing four injections are required to protect against all five serogroups. This immunisation regimen, coupled with low awareness of the disease, can lead to sub-optimal immunisation coverage rates, particularly for MenB, with an estimated coverage of only approximately 31% of adolescents in the US," the company stated. Tony Wood, Chief Scientific Officer at GSK, said: "These statistically significant phase III data are a very encouraging step toward reducing the incidence of meningococcal disease. In the US, routine use of a 5-in-1 meningococcal vaccine with a two-dose regimen in adolescents at 16 to 18 years of age, just before this disease’s incidence peak, could drive significant public health impact. In addition, our 5-in-1 meningococcal vaccine candidate builds on our global leadership in meningococcal vaccines and commitment to innovation."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on GSK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles